Pharmaceutical

CymaBay seeks FDA approval for primary biliary cholangitis therapy

CymaBay Therapeutics has filed a new drug application (NDA) with the FDA seeking approval for seladelpar for PBC management.

Dec 18, 2023 - 10:51
CymaBay seeks FDA approval for primary biliary cholangitis therapy
CymaBay Therapeutics has filed a new drug application (NDA) with the FDA seeking approval for seladelpar for PBC management.
Read the original article

Tags:

Previous Article

Biocytogen and Ona enter cancer ADC development deal

Next Article

EMA CHMP recommends Takeda’s Hyqvia for CIDP treatment

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Skin patch for toddlers with peanut allergy shows promising results in late-stage trial

STAT+: Skin patch for toddlers with peanut allergy show...

May 11, 2023

Phase I completion of Sanofi’s vWD therapy demonstrates promise of pipeline

Phase I completion of Sanofi’s vWD therapy demonstrates...

May 16, 2023

STAT+: FDA scolds Novartis over a misleading TV ad for a breast cancer treatment

STAT+: FDA scolds Novartis over a misleading TV ad for ...

Jan 20, 2024